<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00456807</url>
  </required_header>
  <id_info>
    <org_study_id>109801</org_study_id>
    <nct_id>NCT00456807</nct_id>
  </id_info>
  <brief_title>Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged &gt;/= 26 Years</brief_title>
  <official_title>Complementary Testing to Further Evaluate the Immunogenicity of a GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Aged Over 26 Years Enrolled in Study 104820.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Infection with human papillomavirus (HPV) has been clearly established as the central cause
      of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the
      uterus or womb). This infection may go away by itself, but if it does not go away (this is
      called persistent infection), it can lead in women over a long period of time to cancer of
      the cervix. This study will supplement an ongoing study evaluating the safety, efficacy and
      immunogenicity of the vaccine in women aged 26 years and above. This study will therefore
      assess additional immunogenicity parameters of the vaccine in women from selected
      investigative sites.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Cytokine-positive CD4/CD8 Cells Per Million in Tests Producing at Least 2 Different Cytokines</measure>
    <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
    <description>The geometric mean and 95% confidence interval of the number of Human Papilloma Virus type 16 (HPV-16) and HPV-18 specific CD4 and CD8 cells producing at least 2 different cytokines is reported per million of CD4 or CD8 T-cells, respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of B-cells Per Million Showing a Specific Memory Response for HPV-16 and HPV-18</measure>
    <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
    <description>The geometric mean and 95% confidence interval of the number of HPV-16 and HPV-18 specific memory B-cells is reported per million of B-cells.
An arbitrary value of 0 was given for subjects with antibody concentration below the limit of quantification.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations Above Pre-defined Cut-off Values</measure>
    <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
    <description>Cut-off values assessed include 8 enzyme-linked immunosorbent assay units Per Milliliter (EL.U/mL)for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Titers of Anti-HPV-16 and Anti-HPV-18 Antibodies</measure>
    <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
    <description>Titers are presented as Geometric Mean Titers (GMTs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) Immunoglobulin G (IgG) Antibodies</measure>
    <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
    <description>Titers given as Geometric Mean Titers (GMTs). An arbitrary value of 0 was given for subjects with antibody concentration below the limit of quantification.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of Anti-HPV-16 and Anti-HPV-18 Antibodies in Serum and in Cervical Secretion (CVS) Samples</measure>
    <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
    <description>Pearson coefficients of correlation between serum and CVS for anti-HPV-16 and anti-HPV-18 titers standardized for total IgG were calculated.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Infections, Papillomavirus</condition>
  <arm_group>
    <arm_group_label>Cervarix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects who received 3 doses of placebo during the primary study (NCT00294047).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cervarix TM</intervention_name>
    <description>Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.</description>
    <arm_group_label>Cervarix Group</arm_group_label>
    <other_name>GSK Biologicals' HPV-16/18 VLP/AS04 vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A female enrolled in study 104820 and who received three doses of study
             vaccine/control.

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol should be enrolled in the study.

          -  Written informed consent obtained from the subject prior to enrolment in this
             ancillary study.

        Exclusion Criteria:

          -  Pregnancy.

          -  Administration of any HPV vaccine other than that foreseen by the study protocol.

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine since study start.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs since
             study start.

          -  Administration of immunoglobulins and/or any blood products within 90 days preceding a
             blood sampling.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>26 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Delft</city>
        <zip>2625 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2007</study_first_submitted>
  <study_first_submitted_qc>April 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2007</study_first_posted>
  <results_first_submitted>November 12, 2009</results_first_submitted>
  <results_first_submitted_qc>June 29, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2010</results_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Papillomavirus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>109801</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109801</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109801</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109801</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109801</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109801</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects enrolled at pre-selected sites in the primary study HPV-015 (NCT00294047) who were in the immunogenicity subset and have received all three doses of vaccine/control were asked to participate in the present ancillary study.</recruitment_details>
      <pre_assignment_details>This ancillary study will consist of supplemental testing of serological and cervical samples obtained at Visit 5 (Month 12) and Visit 6 (Month 18) of the primary study HPV-015 (NCT00294047) from pre-selected sites.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cervarix Group</title>
          <description>Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Subjects who received 3 doses of placebo during the primary study (NCT00294047).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cervarix Group</title>
          <description>Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Subjects who received 3 doses of placebo during the primary study (NCT00294047).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.9" spread="8.44"/>
                    <measurement group_id="B2" value="40.3" spread="8.83"/>
                    <measurement group_id="B3" value="40.6" spread="8.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Cytokine-positive CD4/CD8 Cells Per Million in Tests Producing at Least 2 Different Cytokines</title>
        <description>The geometric mean and 95% confidence interval of the number of Human Papilloma Virus type 16 (HPV-16) and HPV-18 specific CD4 and CD8 cells producing at least 2 different cytokines is reported per million of CD4 or CD8 T-cells, respectively.</description>
        <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
        <population>Analysis was performed on subjects from the Total Vaccinated Cohort with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects who received 3 doses of placebo during the primary study (NCT00294047).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cytokine-positive CD4/CD8 Cells Per Million in Tests Producing at Least 2 Different Cytokines</title>
          <description>The geometric mean and 95% confidence interval of the number of Human Papilloma Virus type 16 (HPV-16) and HPV-18 specific CD4 and CD8 cells producing at least 2 different cytokines is reported per million of CD4 or CD8 T-cells, respectively.</description>
          <population>Analysis was performed on subjects from the Total Vaccinated Cohort with available results.</population>
          <units>cells per million CD4/CD8 T-cells</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16 specific CD4 [Month 12] (n=52,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="877.4" lower_limit="665.0" upper_limit="1157.7"/>
                    <measurement group_id="O2" value="19.5" lower_limit="9.4" upper_limit="40.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 specific CD4 [Month 18] (n=52,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="738.5" lower_limit="512.9" upper_limit="1063.3"/>
                    <measurement group_id="O2" value="22.3" lower_limit="11.3" upper_limit="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 specific CD8 [Month 12] (n=52,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.3" upper_limit="3.1"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.2" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 specific CD8 [Month 18] (n=50,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.8" upper_limit="4.7"/>
                    <measurement group_id="O2" value="2.7" lower_limit="1.6" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 specific CD4 [Month 12] (n=52,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="581.2" lower_limit="428.0" upper_limit="789.2"/>
                    <measurement group_id="O2" value="11.5" lower_limit="5.7" upper_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 specific CD4 [Month 18] (n=52,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300.1" lower_limit="171.9" upper_limit="524.1"/>
                    <measurement group_id="O2" value="16.8" lower_limit="9.1" upper_limit="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 specific CD8 [Month 12] (n=52,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.3" upper_limit="3.3"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.1" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 specific CD8 [Month 18] (n=50,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="1.7" upper_limit="4.6"/>
                    <measurement group_id="O2" value="4.7" lower_limit="2.6" upper_limit="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of B-cells Per Million Showing a Specific Memory Response for HPV-16 and HPV-18</title>
        <description>The geometric mean and 95% confidence interval of the number of HPV-16 and HPV-18 specific memory B-cells is reported per million of B-cells.
An arbitrary value of 0 was given for subjects with antibody concentration below the limit of quantification.</description>
        <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
        <population>Analysis was performed on subjects from the Total Vaccinated Cohort with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects who received 3 doses of placebo during the primary study (NCT00294047).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of B-cells Per Million Showing a Specific Memory Response for HPV-16 and HPV-18</title>
          <description>The geometric mean and 95% confidence interval of the number of HPV-16 and HPV-18 specific memory B-cells is reported per million of B-cells.
An arbitrary value of 0 was given for subjects with antibody concentration below the limit of quantification.</description>
          <population>Analysis was performed on subjects from the Total Vaccinated Cohort with available results.</population>
          <units>cells per million B-cells</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16 specific [Month 12] (n=51,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="517.1" lower_limit="361.4" upper_limit="739.9"/>
                    <measurement group_id="O2" value="101.4" lower_limit="45.1" upper_limit="227.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 specific [Month 18] (n=51,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304.4" lower_limit="210.0" upper_limit="441.1"/>
                    <measurement group_id="O2" value="33.1" lower_limit="6.7" upper_limit="163.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 specific [Month 12] (n=51,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354.7" lower_limit="253.1" upper_limit="497.1"/>
                    <measurement group_id="O2" value="68.4" lower_limit="27.0" upper_limit="173.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 specific [Month 18] (n=51,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301.5" lower_limit="223.9" upper_limit="406.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations Above Pre-defined Cut-off Values</title>
        <description>Cut-off values assessed include 8 enzyme-linked immunosorbent assay units Per Milliliter (EL.U/mL)for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
        <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
        <population>Analysis was performed on subjects from the Total Vaccinated Cohort with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects who received 3 doses of placebo during the primary study (NCT00294047).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations Above Pre-defined Cut-off Values</title>
          <description>Cut-off values assessed include 8 enzyme-linked immunosorbent assay units Per Milliliter (EL.U/mL)for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
          <population>Analysis was performed on subjects from the Total Vaccinated Cohort with available results.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16 [Month 12] (n=52, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16 [Month 18] (n=49, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 [Month 12] (n=52, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 [Month 18] (n=49, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Titers of Anti-HPV-16 and Anti-HPV-18 Antibodies</title>
        <description>Titers are presented as Geometric Mean Titers (GMTs).</description>
        <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
        <population>Analysis was performed on subjects from the Total Vaccinated Cohort with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects who received 3 doses of placebo during the primary study (NCT00294047).</description>
          </group>
        </group_list>
        <measure>
          <title>Titers of Anti-HPV-16 and Anti-HPV-18 Antibodies</title>
          <description>Titers are presented as Geometric Mean Titers (GMTs).</description>
          <population>Analysis was performed on subjects from the Total Vaccinated Cohort with available results.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16 [Month 12] (n=52, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2050.4" lower_limit="1456.1" upper_limit="2887.3"/>
                    <measurement group_id="O2" value="6.9" lower_limit="5.3" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-16 [Month 18] (n=49, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1517.1" lower_limit="1067.4" upper_limit="2156.4"/>
                    <measurement group_id="O2" value="7.2" lower_limit="5.4" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 [Month 12] (n=52, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="761.4" lower_limit="538.0" upper_limit="1077.5"/>
                    <measurement group_id="O2" value="4.8" lower_limit="3.5" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 [Month 18] (n=49, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="551.4" lower_limit="387.5" upper_limit="784.6"/>
                    <measurement group_id="O2" value="4.9" lower_limit="3.6" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) Immunoglobulin G (IgG) Antibodies</title>
        <description>Titers given as Geometric Mean Titers (GMTs). An arbitrary value of 0 was given for subjects with antibody concentration below the limit of quantification.</description>
        <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data. None of the subjects in the Placebo Group had detectable antibodies against HPV-16 at Months 12 and 18 and against HPV-18 at Month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects who received 3 doses of placebo during the primary study (NCT00294047).</description>
          </group>
        </group_list>
        <measure>
          <title>Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) Immunoglobulin G (IgG) Antibodies</title>
          <description>Titers given as Geometric Mean Titers (GMTs). An arbitrary value of 0 was given for subjects with antibody concentration below the limit of quantification.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data. None of the subjects in the Placebo Group had detectable antibodies against HPV-16 at Months 12 and 18 and against HPV-18 at Month 12.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV16 [Month 12] (n=12, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.5" lower_limit="58.0" upper_limit="289.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV16 [Month 18] (n=26, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.9" lower_limit="48.9" upper_limit="203.8"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV18 [Month 12] (n=12, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" lower_limit="28.6" upper_limit="158.0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV18 [Month 18] (n=26, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.8" lower_limit="23.1" upper_limit="79.6"/>
                    <measurement group_id="O2" value="5.8" lower_limit="5.8" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Correlation of Anti-HPV-16 and Anti-HPV-18 Antibodies in Serum and in Cervical Secretion (CVS) Samples</title>
        <description>Pearson coefficients of correlation between serum and CVS for anti-HPV-16 and anti-HPV-18 titers standardized for total IgG were calculated.</description>
        <time_frame>At Month 12 and Month 18 after first vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort, only on those subjects from the Cervarix group with CVS sample results available.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects who received 3 doses of placebo during the primary study (NCT00294047).</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Anti-HPV-16 and Anti-HPV-18 Antibodies in Serum and in Cervical Secretion (CVS) Samples</title>
          <description>Pearson coefficients of correlation between serum and CVS for anti-HPV-16 and anti-HPV-18 titers standardized for total IgG were calculated.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort, only on those subjects from the Cervarix group with CVS sample results available.</population>
          <units>correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HVP-16 (Month 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti- HPV-16 (Month 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 (Month 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 (Month 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No safety data were collected in the framework of this ancillary study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cervarix Group</title>
          <description>Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Subjects who received 3 doses of placebo during the primary study (NCT00294047).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No safety data were collected in the framework of this ancillary study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

